The GMTRAMP-C vaccine was administered to enhance the response of TRAMP to antigenic challenge, and TRAMP mice with strong antigenic challenge were then treated with anti CTLA-4, a protein on T cells that prevents T cells from killing other cells, including cancer cells, and anti-CTLA-4 Treatment causes T cells in TRAMP mice to be active and attack prostate tissue, causing damage and thus prostatitis. Here, CTLA4 is linked to prostatitis.